Celltrion has chosen MediMabBio as one of the four biotech startups for its Open Innovation Program. This initiative, in partnership with Seoul Biohub, is part of Celltrion’s strategy to drive innovation and progress in the biotech industry. MediMabBio, recognized for its potential and innovative approach, will benefit from Celltrion’s extensive network, resources, and expertise. This opportunity is aimed at accelerating the development and impact of MediMabBio, bolstering their roles in advancing biotechnological research and applications.